Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
NYSE:JNJ's Cash to Debt is ranked lower than
55% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.46 vs. NYSE:JNJ: N/A )
Ranked among companies with meaningful Cash to Debt only.
NYSE:JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.64 Max: 6.28
Current: N/A
0.46
6.28
Equity to Asset 0.53
NYSE:JNJ's Equity to Asset is ranked lower than
64% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:JNJ: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.53
0.5
0.67
Interest Coverage 34.74
NYSE:JNJ's Interest Coverage is ranked higher than
58% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.31 vs. NYSE:JNJ: 34.74 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.54 Max: 208.73
Current: 34.74
28.29
208.73
F-Score: 6
Z-Score: 5.67
M-Score: -2.64
WACC vs ROIC
7.28%
28.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.71
NYSE:JNJ's Operating margin (%) is ranked higher than
88% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.80 vs. NYSE:JNJ: 26.71 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.14 Max: 28.2
Current: 26.71
22.36
28.2
Net-margin (%) 20.97
NYSE:JNJ's Net-margin (%) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.05 vs. NYSE:JNJ: 20.97 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 21.99
Current: 20.97
14.87
21.99
ROE (%) 20.97
NYSE:JNJ's ROE (%) is ranked higher than
85% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. NYSE:JNJ: 20.97 )
Ranked among companies with meaningful ROE (%) only.
NYSE:JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 20.97
17.02
30.17
ROA (%) 11.20
NYSE:JNJ's ROA (%) is ranked higher than
83% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. NYSE:JNJ: 11.20 )
Ranked among companies with meaningful ROA (%) only.
NYSE:JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.2
8.93
17.08
ROC (Joel Greenblatt) (%) 92.07
NYSE:JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. NYSE:JNJ: 92.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 92.07
65.66
114.87
Revenue Growth (3Y)(%) 1.40
NYSE:JNJ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NYSE:JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.20 Max: 13.8
Current: 1.4
1.4
13.8
EBITDA Growth (3Y)(%) 9.30
NYSE:JNJ's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. NYSE:JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 11.20 Max: 17.3
Current: 9.3
-6.6
17.3
EPS Growth (3Y)(%) 12.40
NYSE:JNJ's EPS Growth (3Y)(%) is ranked higher than
60% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. NYSE:JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.20 Max: 18.2
Current: 12.4
-8.6
18.2
» NYSE:JNJ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

JNJ Guru Trades in Q3 2015

Jim Simons 392,000 sh (New)
Chuck Royce 9,000 sh (New)
Charles Brandes 118,509 sh (New)
Louis Moore Bacon 63,428 sh (New)
John Burbank 32,624 sh (New)
Manning & Napier Advisors, Inc 4,406,762 sh (+33.86%)
Sarah Ketterer 1,593,359 sh (+31.91%)
RS Investment Management 10,457 sh (+21.90%)
Jeff Auxier 110,226 sh (+19.91%)
Pioneer Investments 2,381,190 sh (+15.13%)
John Rogers 884,154 sh (+13.06%)
Yacktman Focused Fund 2,600,000 sh (+4.00%)
Yacktman Fund 3,600,000 sh (+2.86%)
John Buckingham 64,896 sh (+2.30%)
Donald Yacktman 7,560,334 sh (+1.59%)
Tom Gayner 582,200 sh (+1.39%)
Murray Stahl 30,179 sh (+1.13%)
Mairs and Power 2,181,707 sh (+1.09%)
Mario Gabelli 317,847 sh (+0.86%)
T Rowe Price Equity Income Fund 4,672,800 sh (+0.86%)
Ken Fisher 10,689,483 sh (+0.45%)
Robert Olstein 71,000 sh (unchged)
Richard Pzena 1,174,169 sh (unchged)
Warren Buffett 327,100 sh (unchged)
John Hussman 1,325 sh (unchged)
Prem Watsa 82,850 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,270 sh (unchged)
Richard Perry 292,729 sh (unchged)
Michael Price 25,000 sh (unchged)
David Dreman Sold Out
Ruane Cunniff 76,400 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 15,399,839 sh (-1.49%)
First Eagle Investment 1,585,928 sh (-1.50%)
Tweedy Browne 3,855,936 sh (-1.60%)
Dodge & Cox 36,935 sh (-3.40%)
PRIMECAP Management 10,575,867 sh (-6.99%)
Jeremy Grantham 11,529,743 sh (-10.67%)
Ray Dalio 167,593 sh (-14.05%)
Paul Tudor Jones 47,878 sh (-24.52%)
» More
Q4 2015

JNJ Guru Trades in Q4 2015

Joel Greenblatt 39,586 sh (New)
John Hussman 26,325 sh (+1886.79%)
John Burbank 68,755 sh (+110.75%)
First Eagle Investment 3,032,177 sh (+91.19%)
Jim Simons 655,300 sh (+67.17%)
Pioneer Investments 3,824,174 sh (+60.60%)
Charles Brandes 151,094 sh (+27.50%)
Mario Gabelli 332,287 sh (+4.54%)
Tom Gayner 605,200 sh (+3.95%)
John Buckingham 65,746 sh (+1.31%)
Ken Fisher 10,815,964 sh (+1.18%)
Mairs and Power 2,184,308 sh (+0.12%)
Richard Pzena 1,174,524 sh (+0.03%)
T Rowe Price Equity Income Fund 4,672,800 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Robert Olstein 71,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Michael Price 25,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Louis Moore Bacon Sold Out
PRIMECAP Management 10,543,562 sh (-0.31%)
Richard Snow 3,260 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 15,342,046 sh (-0.38%)
Murray Stahl 29,941 sh (-0.79%)
Paul Tudor Jones 46,483 sh (-2.91%)
Donald Yacktman 7,316,129 sh (-3.23%)
Yacktman Focused Fund 2,500,000 sh (-3.85%)
Dodge & Cox 35,435 sh (-4.06%)
Tweedy Browne 3,693,349 sh (-4.22%)
Jeff Auxier 105,426 sh (-4.35%)
John Rogers 831,664 sh (-5.94%)
Sarah Ketterer 1,497,289 sh (-6.03%)
RS Investment Management 9,592 sh (-8.27%)
Jeremy Grantham 9,970,431 sh (-13.52%)
Manning & Napier Advisors, Inc 3,769,800 sh (-14.45%)
Ruane Cunniff 64,753 sh (-15.24%)
Ray Dalio 109,693 sh (-34.55%)
» More
Q1 2016

JNJ Guru Trades in Q1 2016

David Rolfe 5,250 sh (New)
Diamond Hill Capital 1,969 sh (New)
Jim Chanos 29,730 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Tweedy Browne Global Value 865,835 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Richard Snow 3,260 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
Jim Chanos 5,952 sh (unchged)
David Carlson 460,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Perry 292,729 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Yacktman Fund 3,600,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, OTCPK:NVSEF, NYSE:MRK, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHY, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:MAYNF » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Guru Investment Theses on Johnson & Johnson

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Top Ranked Articles about Johnson & Johnson

Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Pharmaceutical sales lead revenue higher for Johnson and Johnson
Johnson & Johnson (NYSE:JNJ) reported its second quarter 2016 earnings results on Tuesday, July 19. The company beat both revenue and earnings estimates for the quarter, helping to fuel continued momentum in U.S. stocks and the health care industry. For the quarter, revenue was $18.48 billion, beating analysts’ average estimate by $500 million. Revenue was also up 4% from the comparable quarter. Earnings for the second quarter were $1.74 beating analysts’ estimate by 6 cents. Read more...
T. Rowe Price Equity Income Fund Sells Apache, Johnson & Johnson in 2nd Quarter Largest sales by the guru firm of the last quarter
The following are his largest sells of the T. Rowe Price Equity Income Fund in the second quarter. Read more...
John Burbank's Best Investments Guru's acquisitions have been paying off
John Burbank (Trades, Portfolio) is the chief investment officer of Passport Capital LLC, the global investment firm he founded in 2000. He manages a portfolio composed of 98 stocks with total value of $6.101 billion. During the first quarter, the guru increased several stakes, and the following are the ones with the best performances since those buys. Read more...
Get Higher Returns and More Dividend Income – In Less Time With Less Risk The power and protection of valuation
Investing in blue-chip dividend growth stocks such as the Dividend Aristocrats or Champions has become very popular with retirees. This is understandable considering the low interest rate environment in which we find ourselves. Traditional fixed income investments do not currently offer enough yield for the retired investor to live on. Consequently, current low interest rates, coupled with the possibility of a steadily increasing level of dividend income have made dividend growth stocks a viable and even attractive alternative. Read more...
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market Johnson & Johnson seeking to develop patentable variations of the drug ketamine
A well-known “party drug” could help Johnson & Johnson (NYSE:JNJ) gain entry into the huge market for antidepressant drugs. Read more...
How to Know When You Can Retire With Dividend Investing The ability to retire with dividend paying stocks is probably broader than you imagine
When I consider the topic of retirement the first thing that comes to mind is John Maynard Keynes' 1930 essay, “Economic Possibilities For Our Grandchildren.” Read more...
Periodic Payments vs. Lump Sum: When's the Right Time to Pull the Plug? A lump sum today may be better than annuity payments
When it comes to investing, the purpose is to receive the biggest reward possible given the prevailing circumstances at the time an investor decides to cash out. Generally, when investing, investors can take two approaches: buy a stock that guarantees periodic dividend payments or simply invest in a stock that promises a massive payout in the future in the form of capital gains. Read more...
Weekly CFO Sells Highlight: Facebook, Johnson & Johnson, PepsiCo Recent insider sales from company CFOs
According to GuruFocus Insider Data, the recent CFO sells were: Facebook Inc. (NASDAQ:FB), Johnson & Johnson (NYSE:JNJ) and PepsiCo Inc. (NYSE:PEP). Read more...
5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Mairs and Power Buys American Express, Pfizer in 3rd Quarter Firm increases stake in American Express by 87%
Mairs and Power (Trades, Portfolio) Inc. is an investment firm whose strength and success has resulted from applying a conservative growth investment approach consistently for over 70 years. The following are its most notable buys during the third quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.48
JNJ's P/E(ttm) is ranked higher than
63% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.13 vs. JNJ: 23.48 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 23.48
10.5
24
Forward P/E 18.90
JNJ's Forward P/E is ranked lower than
63% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.13 vs. JNJ: 18.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.48
JNJ's PE(NRI) is ranked higher than
63% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.09 vs. JNJ: 23.48 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.63 Max: 24
Current: 23.48
10.5
24
Price/Owner Earnings (ttm) 21.32
JNJ's Price/Owner Earnings (ttm) is ranked higher than
72% of the 271 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.32 vs. JNJ: 21.32 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.56 Max: 25.26
Current: 21.32
10.19
25.26
P/B 4.74
JNJ's P/B is ranked lower than
70% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.98 vs. JNJ: 4.74 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 5.26
Current: 4.74
2.68
5.26
P/S 5.00
JNJ's P/S is ranked lower than
67% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. JNJ: 5.00 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 5.01
Current: 5
2.17
5.01
PFCF 24.02
JNJ's PFCF is ranked lower than
52% of the 201 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.87 vs. JNJ: 24.02 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.53 Max: 24.67
Current: 24.02
10.28
24.67
POCF 19.34
JNJ's POCF is ranked lower than
55% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.82 vs. JNJ: 19.34 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.19 Max: 19.35
Current: 19.34
8.98
19.35
EV-to-EBIT 17.68
JNJ's EV-to-EBIT is ranked higher than
59% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.83 vs. JNJ: 17.68 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.90 Max: 18.2
Current: 17.68
7.8
18.2
EV-to-EBITDA 15.34
JNJ's EV-to-EBITDA is ranked higher than
59% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.31 vs. JNJ: 15.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.90 Max: 15.6
Current: 15.34
6.7
15.6
PEG 3.86
JNJ's PEG is ranked lower than
69% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. JNJ: 3.86 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.19  Med: 1.71 Max: 25.96
Current: 3.86
1.19
25.96
Shiller P/E 25.84
JNJ's Shiller P/E is ranked higher than
77% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.92 vs. JNJ: 25.84 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.52  Med: 20.77 Max: 29.97
Current: 25.84
15.52
29.97
Current Ratio 2.83
JNJ's Current Ratio is ranked higher than
58% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. JNJ: 2.83 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.05 Max: 2.83
Current: 2.83
1.2
2.83
Quick Ratio 2.47
JNJ's Quick Ratio is ranked higher than
62% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. JNJ: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.71 Max: 2.47
Current: 2.47
0.94
2.47
Days Inventory 138.17
JNJ's Days Inventory is ranked lower than
63% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. JNJ: 138.17 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.17
100.19
137.6
Days Sales Outstanding 58.74
JNJ's Days Sales Outstanding is ranked higher than
63% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. JNJ: 58.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 58.74
53.94
61.4
Days Payable 100.98
JNJ's Days Payable is ranked higher than
69% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.75 vs. JNJ: 100.98 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 100.98
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.44
JNJ's Dividend Yield is ranked higher than
73% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. JNJ: 2.44 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 1.89  Med: 2.84 Max: 3.84
Current: 2.44
1.89
3.84
Dividend Payout 0.55
JNJ's Dividend Payout is ranked lower than
70% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. JNJ: 0.55 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.42 Max: 6.33
Current: 0.55
0.29
6.33
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
51% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13.00 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.56
JNJ's Forward Dividend Yield is ranked higher than
71% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. JNJ: 2.56 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.42
JNJ's Yield on cost (5-Year) is ranked higher than
72% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. JNJ: 3.42 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.65  Med: 3.98 Max: 5.39
Current: 3.42
2.65
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 420 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.20 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.10 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.82
JNJ's Price/Tangible Book is ranked lower than
88% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. JNJ: 13.82 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.41 Max: 18.92
Current: 13.82
6.24
18.92
Price/Projected FCF 1.84
JNJ's Price/Projected FCF is ranked higher than
64% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.65 vs. JNJ: 1.84 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.40 Max: 3.6
Current: 1.84
0.87
3.6
Price/DCF (Earnings Based) 2.20
JNJ's Price/DCF (Earnings Based) is ranked lower than
72% of the 78 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. JNJ: 2.20 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.55
JNJ's Price/Median PS Value is ranked lower than
70% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. JNJ: 1.55 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.14 Max: 1.88
Current: 1.55
0.74
1.88
Price/Peter Lynch Fair Value 2.84
JNJ's Price/Peter Lynch Fair Value is ranked lower than
73% of the 164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.57 vs. JNJ: 2.84 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.22  Med: 1.88 Max: 4.03
Current: 2.84
1.22
4.03
Price/Graham Number 3.74
JNJ's Price/Graham Number is ranked lower than
70% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. JNJ: 3.74 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.15 Max: 5.97
Current: 3.74
1.97
5.97
Earnings Yield (Greenblatt) (%) 5.72
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. JNJ: 5.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.70 Max: 12.9
Current: 5.72
5.5
12.9
Forward Rate of Return (Yacktman) (%) 11.72
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. JNJ: 11.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.00 Max: 18.4
Current: 11.72
1.8
18.4

More Statistics

Revenue (TTM) (Mil) $70,877
EPS (TTM) $ 5.32
Beta0.80
Short Percentage of Float0.87%
52-Week Range $81.79 - 126.07
Shares Outstanding (Mil)2,750.64

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 71,796 74,943 77,258
EPS ($) 6.64 7.08 7.42
EPS w/o NRI ($) 6.64 7.08 7.42
EPS Growth Rate
(3Y to 5Y Estimate)
3.38%
Dividends Per Share ($) 3.11 3.27 3.39
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
T. Rowe Price Equity Income Fund Sells Apache, Johnson & Johnson in 2nd Quarter Jul 21 2016 
What Will Happen to the Stock Market When Interest Rates Rise? Part 1 Jul 21 2016 
Microsoft in Focus as Stock Valuation Gains Ease Slightly Jul 19 2016 
Yacktman Focused Fund, Focuses Elsewhere Jul 19 2016 
Can the Procter & Gamble’s Find Its Lost Mojo? Jul 19 2016 
Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
Avoid Getting Sucked In at the Top Jul 17 2016 
Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
First Half 2016 Review Jul 06 2016 

More From Other Websites
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016
[$$] Johnson & Johnson's Acclarent Unit in $18 Million U.S. Settlement Jul 22 2016
How Did JNJ’s Pharmaceutical Segment Fare in 2Q16? Jul 22 2016
How Did Johnson & Johnson’s Segments Perform in 2Q16? Jul 22 2016
Why Johnson & Johnson’s 2Q16 Profits Fell by 11.5% Jul 22 2016
J&J unit Acclarent to pay $18 mln to settle false claims case Jul 22 2016
Animal Spirits Have Returned Jul 22 2016
Don't Disrespect This Bull Market Jul 22 2016
What Will Happen to the Stock Market When Interest Rates Rise? Part 1 Jul 21 2016
Two Former Johnson & Johnson Execs Just Got Convicted for Improper Marketing Jul 21 2016
Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche Bank Jul 21 2016
Research Reports on Facebook (FB), Tesla (TSLA) & Others Jul 21 2016
3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings Jul 21 2016
How Were Johnson & Johnson’s 2Q16 Earnings Trending? Jul 21 2016
How Did Johnson & Johnson Fare in 2Q16? Jul 21 2016
Johnson & Johnson :JNJ-US: Earnings Analysis: Q2, 2016 By the Numbers : July 21, 2016 Jul 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)